Articles

Pre- and postmarketing psoriasis studies support novel drug results and new labeling.



Novel Therapeutics Usher in a Year of Innovation

Dermavant announces positive results from an interim analysis of its PSOARING 3 safety study investigating tapinarof cream 1% for the treatment of plaque psoriasis in adult patients. 

Phase 3 Results Support Long-Term Use of Tapinarof Cream

According to one expert, recently completed phase 3 trials of novel drugs have shown impressive results, with 2021  expected to be an exciting year that will bring further advances in treatment options for patients with moderate-to-severe plaque psoriasis.

New Year, New drugs for Psoriasis

New AAD-NPF guidelines focus on biologics, topical therapy, systemic non-biological therapies, management of pediatric patients, use of phototherapy and comorbidities. 

New AAD-NPF Psoriasis Guidelines Mark Changes

A proprietary food supplement designed to balance the gut microbiome and target the over production of skin cells will be examined in an upcoming consumer study that has recently announced participant enrollment. 

Enrollment Begins for Food Supplement, Skin Inflammation Study

Safety profiles remain consistent longer-term but cost and accessibility are major challenges for biologics aimed at treating psoriasis. 

IL Inhibitors and TYK2 Blocker Near Approval 

Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.

Expanding Line of Therapeutic Agents for Psoriasis 

According to a study conducted by Galderma, both rosacea and psoriasis have a significant QOL impact on patients, with a proportion of patients reporting feelings of anxiety and depression due to their disease. 


Quality of life, mental health issues common in rosacea, PsO patients 

John Jesitus is a medical writer based in Westminster, CO.

Genetic polymorphisms may increase psoriasis susceptibility, according to a study that found patients who have the G allele in the JAK1 gene have twice the risk of developing psoriasis, and for those with the JAK3 allele, the risk rises nearly 2-fold.

JAKs may predict psoriasis risk 

Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients switching from placebo to guselkumab. 